Brisbane, Australia and Minneapolis, USA. Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) announces its submission at this year’s Transcatheter Cardiovascular Therapeutics (TCT) conference at Orlando, Florida, United States was accepted into the innovation session.

The TCT conference, running from November 4 to 6, is the largest and most prestigious Interventional cardiology meeting held each year and will return to an “in-person” meeting format.

The innovation component of TCT is reserved for emerging technologies that are novel, clinically relevant/important and are judged relative to other technologies within the same class, either in the market or in development.

Submissions for the technology session number at approximately 100 of which 25 across all areas are selected for presentation as innovative. These include mitral, TAVR, LAAO and many others.

The selection committee is made up of physicians regarded as being leading experts in the field of interventional cardiology globally.

“Being recognized by the selection committee in this highly competitive component of TCT is further validation of how clinically relevant DurAVRTM is for the treatment of younger patients with aortic stenosis. The unique hemodynamic profile, ADAPT® premium and proven superior anti-calcification treatment, and novel 3D unibody design, giving greater structural integrity, offers a solution for younger patients with aortic stenosis. The Innovation sessions are keenly observed by physicians, analysts and senior industry executives. The potential of this product to fill the treatment gap for younger patients needing longer lasting and better working valves is being recognized within the medical community,” Anteris CEO Wayne Paterson said.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT® tissue technology, paired with DurAVR™’s unique 3D single-piece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Authorisation and Additional information This announcement was authorised by the Board of Directors.

For more information: Hannah Howlett WE Communications E: WE-AUAnterisTech@we-worldwide.com P: +61 4 5064 8064 www.anteristech.com Twitter: @AnterisTech Facebook: www.facebook.com/AnterisTech